1. Trang chủ >
  2. Y Tế - Sức Khỏe >
  3. Y học thưởng thức >

Appendix 2. Reviewer Relationships With Industry And Other Entities (Relevant)— 2011 Accf/Aha Guideline For Coronary Artery Bypass Graft Surgery

Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (1.51 MB, 88 trang )


e208



Hillis et al.

2011 ACCF/AHA CABG Guideline



Peer Reviewer



Representation

Organizational

Reviewer—SCA



None



Joseph S.

Alpert



Content Reviewer







Robert M.

Califf



Content Reviewer

















Content Reviewer



Speaker’s

Bureau



Consultant



Stanton K.

Shernan



Robbin G.

Cohen



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210







Philips

Healthcare



Ownership/

Partnership/

Principal



Personal

Research

None



None







None



None



None



None



None







None



None



None



AstraZeneca

Daiichi-Sankyo

GlaxoSmithKline

Medtronic

Sanofi-aventis



None



None









None



Expert

Witness



None



Bayer

Sanofi-aventis



None



Institutional,

Organizational, or

Other Financial

Benefit



None



Eli Lilly†

Bayer



None











Defendant, death

after minimally

invasive heart

surgery, 2011

Defendant,

diagnosis of aortic

dissection, 2010

Plaintiff, renal

failure and

Aprotinin, 2010



None



None







Merck



None







None



None







Medtronic



None



None



None



None



None



None







None



None



None



None



None



None



Content Reviewer



None



None



None







Anthony P.

Furnary



Content

Reviewer—ACCF

Surgeons’

Scientific

Council



None



None



None



None



Valentin Fuster



Content Reviewer



None



None



None



None



None



None



John W.

Hirshfeld, Jr.



Content Reviewer







GlaxoSmithKline



None



None



None



None



None



Judith S.

Hochman



Content

Reviewer—

ACCF/AHA Task

Force on

Practice

Guidelines







Eli Lilly

GlaxoSmithKline



None



None



None



None



None







James L.

Januzzi, Jr.



Content Reviewer







Roche



None



None







None



None



Frederick G.

Kushner



Content

Reviewer—Vice

Chair, 2012

STEMI Guideline

Writing

Committee



None



None



None



None



None



None



Glenn Levine



Content Review—

Chair, 2011 PCI

Guideline

Writing

Committee



None



None



None



None



None



None



Mark A.

Creager



AstraZeneca

Genzyme

Merck

Roche

Vascutek



Plaintiff,

communication of

echocardiography

results, 2010



Content

Reviewer—

ACCF/AHA Task

Force on

Practice

Guidelines







Steven M.

Ettinger



Content Review—

ACCF/AHA Task

Force on

Practice

Guidelines



None



David P. Faxon



Content Reviewer







Kirsten E.

Fleischmann



Content Reviewer



Lee Fleisher













Sanofi-aventis



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



Pfizer



Roche







AstraZeneca†



None



Plaintiff, Fasudil

Development:

Asahi Pharma v

Actelion, 2010



Defendant, cath

vascular access

site complication,

2009







Defendant,

perioperative

stroke, 2009







Defendant, Bayer

Corp. Trasylol

litigation, 2009 to

2011



Hillis et al.

2011 ACCF/AHA CABG Guideline



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210



Peer Reviewer



Representation



Donald Likosky



Content Reviewer



Speaker’s

Bureau



Consultant

None



None



Ownership/

Partnership/

Principal

None



Personal

Research







James J.

Livesay



Content

None

Reviewer—Southern

Thoracic Surgical

Association



None



None



Maquet†

Medtronic†



None



Institutional,

Organizational, or

Other Financial

Benefit



Expert

Witness



None



None



None















Defendant, acute

aortic dissection,

2011

Defendant,

cardiac mortality

review, 2010

Defendant,

heparin induced

thrombocytopenia,

2010



Bruce W. Lytle



Content

Reviewer—2004

CABG Guideline

Writing

Committee



None



None



None



None



None



None



Robert A.

Marlow



Content

Reviewer—2004

CABG Guideline

Writing

Committee



None



None



None



None



None



None



Rick A.

Nishimura



Content

Reviewer—ACCF

Board of

Trustees



None



None



None



None



None



None



Patrick O’Gara



Content

Reviewer—Chair,

2012 STEMI

Guideline

Writing

Committee



None



None



None



None



None



None



E. Magnus

Ohman



Content

Reviewer—ACCF/

AHA Task Force

on Practice

Guidelines







None







None



None





















AstraZeneca

Bristol-Myers

Squibb

Boehringer

Ingelheim

Gilead Sciences

Merck

Pozen

Sanofi-aventis











Boehringer

Ingelheim

Gilead Sciences









Daiichi-Sankyo

Datascope

Eli Lilly



John D.

Rutherford



Content Reviewer



None



None



None



None



None



None



George A.

Stouffer



Content Reviewer



None



None



None



None



None







Mathew

Williams



Content—ACCF

Interventional

Scientific

Council







None



None



None



None



None







Edwards

Lifesciences

Medtronic



e209



Defendant, review

of malpractice

claim, 2010



This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect

relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of Ն5% of the voting stock or share of the

business entity, or ownership of Ն$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the

previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose

of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

According to the ACCF/AHA, a person has a relevant relationship IF: (a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed

in the document; or (b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the

document; or (c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed

in the document.

*No financial benefit. †Significant relationship.

AATS indicates American Association for Thoracic Surgery; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; CABG, coronary artery bypass graft surgery; PCI,

percutaneous coronary intervention; SCA, Society of Cardiovascular Anesthesiologists; STEMI, ST-elevation myocardial infarction; and STS, Society of Thoracic Surgeons.



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



e210



Hillis et al.

2011 ACCF/AHA CABG Guideline



JACC Vol. 58, No. 24, 2011

December 6, 2011:e123–210



APPENDIX 3. ABBREVIATION LIST

ACE ϭ angiotensin-converting enzyme



LIMA ϭ left internal mammary artery



ACS ϭ acute coronary syndrome



LV ϭ left ventricular



AF ϭ atrial fibrillation



LVEF ϭ left ventricular ejection fraction



AKI ϭ acute kidney injury



MACE ϭ major adverse coronary events



ARB ϭ angiotensin-receptor blockers



MI ϭ myocardial infarction



BMS ϭ bare-metal stent



NSTEMI ϭ non–ST-elevation myocardial infarction



CABG ϭ coronary artery bypass graft surgery



PAC ϭ pulmonary artery catheter



CAD ϭ coronary artery disease



PAD ϭ peripheral artery disease



CKD ϭ chronic kidney disease



PCI ϭ percutaneous coronary intervention



CPB ϭ cardiopulmonary bypass



RCT ϭ randomized controlled trial



DAPT ϭ dual antiplatelet therapy



SIHD ϭ stable ischemic heart disease



DES ϭ drug-eluting stent



SIRS ϭ systemic inflammatory response system



EF ϭ ejection fraction



STEMI ϭ ST-elevation myocardial infarction



GDMT ϭ guideline–directed medical therapy



SVG ϭ saphenous vein graft



ICU ϭ intensive care unit



TEE ϭ transesophageal echocardiography



IMA ϭ internal mammary artery



TIA ϭ transient ischemic attack



LAD ϭ left anterior descending



TMR ϭ transmyocardial laser revascularization



LDL ϭ low-density lipoprotein



UA ϭ unstable angina



Downloaded From: http://content.onlinejacc.org/ on 02/28/2013



Xem Thêm
Tải bản đầy đủ (.pdf) (88 trang)

×